Clinical trial
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
NCT06588478 is registered in ClinicalTrials.gov with Loxo Oncology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
- Lead sponsor
- Loxo Oncology, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 3, 2025
- Completion date
- December 31, 2028
- Enrollment
- 249 (estimated)
- Sites
- 131
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia, small lymphocytic lymphoma